CGBIO Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CGBIO Co., Ltd - overview
Established
2006
Location
Seoul, -, South Korea
Primary Industry
Medical Devices & Equipment
About
Based in Seoul, South Korea, and founded in 2006, CGBIO Co. , Ltd, a. k. a.
CGBIO operates as a medical devices and equipment manufacturer and distributor that focuses on providing allograft and synthetic bone grafts, spinal implants, GMP grade growth factors, and total wound care solution. As of April 2023, Hyun Seung Yu is the CEO of the company. CGBIO provides a wide range of orthopedic, wound, and aesthetic medical equipment, including anti-adhesion barrier, rhBMP-2, rhBMP-2 + HA carrier, filler, automated SVF isolation system, cryopreserved acellular Dermal Matrix, spine implant, and more. The company utilizes tissue scaffold, growth factor, and cell solution biotechnology necessary for tissue regeneration, in order to innovate solutions for the management of spinal diseases and wounds.
Primary Industry
Medical Devices & Equipment
Sub Industries
Biotechnology, Healthcare, Chiropractic, Orthopedic & Physical Therapy, Medical Equipment Distributors
Website
www.cgbio.co.kr
Verticals
3D Printing, Manufacturing
Total Amount Raised
Subscriber access only
CGBIO Co., Ltd - timeline of key events
CGBIO Co., Ltd - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 20,694,715,639 | 26,411,161,372 | 32,759,546,281 | 41,055,685,474 | 40,565,414,503 | 51,710,228,998 | 61,984,708,615 | 71,424,426,995 | 94,554,171,731 | 129,703,455,137 | - | - | - |
| % Revenue Growth (YoY) | - | 27.6% | 24.0% | 25.3% | (1.2%) | 27.5% | 19.9% | 15.2% | 32.4% | 37.2% | - | - | - |
| EBITDA (USD) | 2,488,825,404 | (257,303,324) | 449,997,536 | 6,319,904,275 | 4,817,488,612 | 6,687,738,929 | 10,799,302,930 | 14,602,742,313 | 19,926,665,536 | 23,267,391,084 | - | - | - |
| Operating Income (USD) | 2,229,676,462 | (1,032,531,819) | (649,756,533) | 4,813,249,923 | 2,805,538,247 | 4,283,719,648 | 8,435,791,863 | 10,916,326,779 | 16,047,617,609 | 18,162,445,939 | - | - | - |
| Operating Margin | 10.8% | (3.9%) | (2.0%) | 11.7% | 6.9% | 8.3% | 13.6% | 15.3% | 17.0% | 14.0% | - | - | - |
| % EBITDA Margin | 12.0% | (1.0%) | 1.4% | 15.4% | 11.9% | 12.9% | 17.4% | 20.4% | 21.1% | 17.9% | - | - | - |
| NET Income (USD) | 580,724,819 | (2,032,440,231) | (1,180,111,905) | 4,602,095,972 | 2,179,626,779 | 3,588,694,840 | 7,537,876,154 | 9,390,621,391 | 17,254,790,786 | 15,813,036,013 | - | - | - |
| % Net Margin | 2.8% | (7.7%) | (3.6%) | 11.2% | 5.4% | 6.9% | 12.2% | 13.1% | 18.2% | 12.2% | - | - | - |
CGBIO Co., Ltd - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.